Adjuvant sintilimab effective in high-risk HCC

被引：3
|
作者：
Sidaway P.
机构：
[1] Nature Reviews Clinical Oncology,
来源：
Nature Reviews Clinical Oncology | 2024年 / 21卷 / 3期
关键词：
D O I：
10.1038/s41571-024-00865-3
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：168 / 168
相关论文
共 50 条
  • [1] Adjuvant sintilimab effective in high-risk HCC
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (03) : 168 - 168
  • [2] Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence
    Jordan Hindson
    Nature Reviews Gastroenterology & Hepatology, 2024, 21 : 141 - 141
  • [3] Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence
    Hindson, Jordan
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2024, 21 (03) : 141 - 141
  • [4] Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
    Wang, Kang
    Xiang, Yan-Jun
    Yu, Hong-Ming
    Cheng, Yu-Qiang
    Liu, Zong-Han
    Qin, Ying-Yi
    Shi, Jie
    Guo, Wei-Xing
    Lu, Chong-De
    Zheng, Ya-Xin
    Zhou, Fei-Guo
    Yan, Mao-Lin
    Zhou, Hong-Kun
    Liang, Chao
    Zhang, Fan
    Wei, Wen-Jing
    Lau, Wan Yee
    Li, Jing-Jing
    Liu, Yan-Fang
    Cheng, Shu-Qun
    NATURE MEDICINE, 2024, 30 (03) : 708 - +
  • [5] Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
    Kang Wang
    Yan-Jun Xiang
    Hong-Ming Yu
    Yu-Qiang Cheng
    Zong-Han Liu
    Ying-Yi Qin
    Jie Shi
    Wei-Xing Guo
    Chong-De Lu
    Ya-Xin Zheng
    Fei-Guo Zhou
    Mao-Lin Yan
    Hong-Kun Zhou
    Chao Liang
    Fan Zhang
    Wen-Jing Wei
    Wan Yee Lau
    Jing-Jing Li
    Yan-Fang Liu
    Shu-Qun Cheng
    Nature Medicine, 2024, 30 : 708 - 715
  • [6] GALAD score is effective for HCC surveillance among high-risk patients
    Hirode, Grishma
    Zangneh, Hooman Farhang
    Cerocchi, Orlando
    El-Karim, Lima Awad
    Khalili, Korosh
    Janssen, Harry L. A.
    Hansen, Bettina E.
    Feld, Jordan J.
    JOURNAL OF HEPATOLOGY, 2024, 80 : S49 - S49
  • [7] EFFECTIVE SURGICAL ADJUVANT THERAPY FOR HIGH-RISK RECTAL-CARCINOMA
    LIVINGSTON, EH
    NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (07): : 519 - 519
  • [8] EFFECTIVE SURGICAL ADJUVANT THERAPY FOR HIGH-RISK RECTAL-CARCINOMA
    KROOK, JE
    MOERTEL, CG
    GUNDERSON, LL
    WIEAND, HS
    COLLINS, RT
    BEART, RW
    KUBISTA, TP
    POON, MA
    MEYERS, WC
    MAILLIARD, JA
    TWITO, DI
    MORTON, RF
    VEEDER, MH
    WITZIG, TE
    CHA, S
    VIDYARTHI, SC
    NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (11): : 709 - 715
  • [9] Adjuvant treatment of high-risk melanoma
    Simon S.C.S.
    Utikal J.
    best practice onkologie, 2021, 16 (7-8) : 308 - 314
  • [10] Adjuvant Therapy for High-Risk Melanoma
    Tarhini, Ahmad A.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2014, 10 (05) : 4 - 13
12345